FilingsTodayBridgeBio Pharma
At a glance
BridgeBio Pharma reported 2025 revenue of $502.1M, up 126.3% from $221.9M in 2024. Over 4 years since 2021 ($69.7M), that is growth of about 63.8% a year. Operating margin was -104.2%, up from -827.1% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2021, 2022, 2023, 2024 and 2025.
In the last 12 months 9 insiders reported 0 open-market purchases and 36 sales ($105M). 33 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $13.2M by Director Jennifer E. Cook on Jul 13, 2026.
BridgeBio Pharma filed 17 current reports (Form 8-K) in the last 12 months, most often for other events (7), results of operations (5), material agreement (4) and unregistered equity sale (2). The latest officer or director change was reported on Jun 26, 2026. It reported a material agreement or a completed acquisition or disposal 4 times.
3 of the 20 investors tracked here held BridgeBio Pharma at the last quarter end, worth $838.2M combined. It is the largest weight for Viking Global Investors (2.1% of its portfolio), followed by Bridgewater Associates (0.1%). Added: Bridgewater Associates and Renaissance Technologies. Reduced: Viking Global Investors.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | - | - | - | - | - |
| Diluted EPS | $-3.90 | $-3.26 | $-3.95 | $-2.88 | $-3.78 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined